Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vitamin A

FDA-approved product (capsule, oral), marketed as Aquasol A, Vitamin A.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Vitamin A
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Eye disease
  • Nasal congestion

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Vitamin a, plain; Retinoids for topical use in acne; Other nasal preparations; Other ophthalmologicals
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Vitamin A, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA20.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli32.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis36.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vitamin A in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vitamin A with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • High Dose Ascorbic Acid Treatment of CMT1A

    NCT00484510 · start 2007-04

    Registered record
    Registry ID
    NCT00484510
    Conditions
    Charcot-Marie-Tooth Disease, Type Ia
    Interventions
    Ascorbic acid (Vitamin C); placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2007-04
    Completion
    2012-12
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCharcot-Marie-Tooth Disease, Type Ia
    InterventionAscorbic acid (Vitamin C); placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Oral Paricalcitol in Kidney Transplant Recipients

    NCT00587158 · start 2007-01

    Registered record
    Registry ID
    NCT00587158
    Conditions
    Transplant; Failure, Kidney; Renal Disease, End Stage; Hyperparathyroidism, Secondary
    Interventions
    Paricalcitol; Corticosteroid Avoidance Immune Suppression Protocol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-01
    Completion
    2011-11
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransplant; Failure, Kidney; Renal Disease, End Stage; Hyperparathyroidism, Secondary
    InterventionParicalcitol; Corticosteroid Avoidance Immune Suppression Protocol
    PhaseNot applicable
    Registry statusCompleted

  • Prenatal Multi-micronutrient Supplementation and Pregnancy Outcome

    NCT00168688 · start 2001-01

    Registered record
    Registry ID
    NCT00168688
    Conditions
    Pregnancy; Birth Weight
    Interventions
    multi micronutrient supplement; MN1; MN2
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-01
    Completion
    2002-10
    Enrolment
    2,100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnancy; Birth Weight
    Interventionmulti micronutrient supplement; MN1; MN2
    PhasePhase 1
    Registry statusCompleted

  • TB Nutrition, Immunology and Epidemiology

    NCT00170404 · start 2000-06

    Registered record
    Registry ID
    NCT00170404
    Conditions
    Mycobacterium Tuberculosis
    Interventions
    Folic Acid; Micronutrients: Vitamins B1, B2, B6, Niacin, B12, C, E.; Selenium; Vitamin A
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-06
    Completion
    2005-10
    Enrolment
    887

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Tuberculosis
    InterventionFolic Acid; Micronutrients: Vitamins B1, B2, B6, Niacin, B12, C, E.; Selenium; Vitamin A
    PhasePhase 3
    Registry statusCompleted

  • ILX23-7553 in Treating Patients With Solid Tumors That Have Not Responded to Previous Therapy

    NCT00004926 · start 1999-10

    Registered record
    Registry ID
    NCT00004926
    Conditions
    Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    vitamin D3 analogue ILX23-7553
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1999-10
    Completion
    2009-12
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnspecified Adult Solid Tumor, Protocol Specific
    Interventionvitamin D3 analogue ILX23-7553
    PhasePhase 1
    Registry statusCompleted